784 bone marrow transplantation (bmt) in children

784 bone marrow transplantation (bmt) in children

Play all audios:

Loading...

ABSTRACT BMT is used with increased frequency to treat aplastic anemia (AA) and acute leukemia (AL). We report the results of 90 BMT performed on children at UCLA through June, 1980. Thirty-three BMT were done on previously transfused AA patients; 18 recipients survive (55%). In 17 of these 33 patients, low-dose (3Gy) total body irradiation (TBI) was added to the cyclophosphamide conditioning regimen (CY) to decrease the risk of graft rejection. Thirteen of these patients survive (76%, median = 791 + d). Failure to use TBI was associated with a 43% rejection rate, while use of 10Gy TBI was associated with an 83% risk of fatal graft versus host disease (GVHD). Fifty-seven patients had BMT for AL. Three of 34 patients transplanted in relapse survive (>3.5 y). There were 6 early deaths; 17 of the remaining 28 patients developed GVHD (16 fatal), and 9 of the remaining 12 patients relapsed. Twenty-three had BMT during remission: there were 2 early deaths, 6 cases of fatal GVHD and 6 patients relapsed. Nine patients survive (39%, median = 264 + d). No relapses occurred among 6 patients who had BMT for AML in first remission, using a matched sibling donor. We conclude that BMT is the treatment of choice for children with severe AA, if a compatible sibling donor is available. Addition of low-dose TBI to CY improves the survival of previously transfused AA patients. BMT offers the possibility of prolonged disease-free survival to patients with ultra-high-risk AL. ARTICLE PDF AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Departments of Pediatrics and Medicine, UCLA School of Medicine, Los Angeles Edward B Arenson, Stephan K Ladisch, Robert P Gale & Stephen A Feig Authors * Edward B Arenson View author publications You can also search for this author inPubMed Google Scholar * Stephan K Ladisch View author publications You can also search for this author inPubMed Google Scholar * Robert P Gale View author publications You can also search for this author inPubMed Google Scholar * Stephen A Feig View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Arenson, E., Ladisch, S., Gale, R. _et al._ 784 BONE MARROW TRANSPLANTATION (BMT) IN CHILDREN. _Pediatr Res_ 15 (Suppl 4), 573 (1981). https://doi.org/10.1203/00006450-198104001-00808 Download citation * Issue Date: 01 April 1981 * DOI: https://doi.org/10.1203/00006450-198104001-00808 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

ABSTRACT BMT is used with increased frequency to treat aplastic anemia (AA) and acute leukemia (AL). We report the results of 90 BMT performed on children at UCLA through June, 1980.


Thirty-three BMT were done on previously transfused AA patients; 18 recipients survive (55%). In 17 of these 33 patients, low-dose (3Gy) total body irradiation (TBI) was added to the


cyclophosphamide conditioning regimen (CY) to decrease the risk of graft rejection. Thirteen of these patients survive (76%, median = 791 + d). Failure to use TBI was associated with a 43%


rejection rate, while use of 10Gy TBI was associated with an 83% risk of fatal graft versus host disease (GVHD). Fifty-seven patients had BMT for AL. Three of 34 patients transplanted in


relapse survive (>3.5 y). There were 6 early deaths; 17 of the remaining 28 patients developed GVHD (16 fatal), and 9 of the remaining 12 patients relapsed. Twenty-three had BMT during


remission: there were 2 early deaths, 6 cases of fatal GVHD and 6 patients relapsed. Nine patients survive (39%, median = 264 + d). No relapses occurred among 6 patients who had BMT for AML


in first remission, using a matched sibling donor. We conclude that BMT is the treatment of choice for children with severe AA, if a compatible sibling donor is available. Addition of


low-dose TBI to CY improves the survival of previously transfused AA patients. BMT offers the possibility of prolonged disease-free survival to patients with ultra-high-risk AL. ARTICLE PDF


AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Departments of Pediatrics and Medicine, UCLA School of Medicine, Los Angeles Edward B Arenson, Stephan K Ladisch, Robert P Gale & Stephen A


Feig Authors * Edward B Arenson View author publications You can also search for this author inPubMed Google Scholar * Stephan K Ladisch View author publications You can also search for this


author inPubMed Google Scholar * Robert P Gale View author publications You can also search for this author inPubMed Google Scholar * Stephen A Feig View author publications You can also


search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Arenson, E., Ladisch, S., Gale, R. _et al._ 784 BONE


MARROW TRANSPLANTATION (BMT) IN CHILDREN. _Pediatr Res_ 15 (Suppl 4), 573 (1981). https://doi.org/10.1203/00006450-198104001-00808 Download citation * Issue Date: 01 April 1981 * DOI:


https://doi.org/10.1203/00006450-198104001-00808 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is


not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative